4 Hrs
Source:
الاقتصادية
Source: الاقتصادية
4 Hrsالاقتصادية
Source: الاقتصادية
4 HrsReady to play
Ready to play
Sanofi raised its 2026 guidance, targeting sales growth in the low double digits and earnings per share growth in the mid-teens, after quarterly results beat expectations. Third-quarter sales reached €14.44 billion, up 14.3%. The company said it was ready to pursue acquisitions larger than its usual $2 billion to $5 billion range to strengthen its drug portfolio, with estimates suggesting it has around €20 billion available for such deals. Dupixent led performance, generating sales of €5.69 billion, while Sanofi works to develop new treatments ahead of the drug’s loss of exclusivity in the early 2030s.
Notice: This Is an AI-Generated Summary
Comments (0)